** Shares of biotech firm Humacyte HUMA.O down 23.5% to $2.20 post-market after stock offering news

** Durham, North Carolina-based firm announces proposed stock offering without disclosing deal size

** Co intends to use net offering proceeds to fund commercialization of its implant Symvess for patients with extreme blood vessel injury

** TD Cowen, Barclays and BTIG jt bookrunners

** With ~122.65 mln shares outstanding, co has ~$353 mln market cap, per LSEG data

** HUMA shares finished Tuesday's session down 13.4% at $2.88. YTD, stock down 43%

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))